In a significant milestone, System Loco has successfully completed regulatory approvals for its unique medical device, marking the commencement of mass production. This achievement comes after an intensive collaboration with a major pharmaceutical company in the United States, where the innovative device is tailored to meet the specific needs of the client.
The shared intellectual property (utility patent pending) resulting from the close partnership, underscores the depth of collaboration between the two companies. The device is not slated for general sale but is exclusively crafted for large-scale deployment within this specific customer’s operations. As the device enters mass production, its impact on enhancing operational efficiency, patient care, and ultimately making surgeries more cost effective is one step closer, with deployment planned throughout 2024.
This focused approach to product development aligns with System Loco’s commitment to delivering tailor-made solutions that cater to the unique requirements of key clients, showcasing the effectiveness of strategic collaborations in pushing the boundaries of IoT technologies in medical applications.
System Loco’s venture into large-scale production for this blue-chip partner not only solidifies its reputation as a key player in the industry but also highlights the adaptability of its technology to address the evolving needs of healthcare giants. This development signifies a noteworthy chapter in the ongoing narrative of technology-driven advancements within the healthcare sector.
System Loco’s roots are in research and development. Our innovative spirit drives us to continually explore new horizons in pharmaceutical asset management. Our team of Ph.D. holders boasts expertise in software engineering, electronic and electrical systems, quality engineering, system design, satellite communication systems, and network security/encryption.
We are trusted partners in developing custom solutions with major pharmaceutical companies in the US and EU.
